An FDA review showed that anti-coagulant rivaroxaban outperformed enoxaparin in stopping blood clots but almost doubled the risk of bleeding. Johnson & Johnson, which developed rivaroxaban with Bayer, said the treatment has a "favorable safety profile" and that all anti-clotting medicines come with bleeding risk. On Thursday, a panel of FDA advisers will evaluate the drug for approval.

Full Story:

Related Summaries